Article
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jun 2026
Morgan Gareth J, Lee Dennis D, Joseph Nisha S, Lonial Sagar, Rodriguez-Otero Paula, San-Miguel Jesús F
Abstract excerpt
Despite therapeutic progress, there has been little improvement in the outcome of the 15%-25% of newly diagnosed high-risk multiple myeloma (HRMM), which is characterized by early treatment resistance and very poor survival. HRMM is a substantial clinical problem both at presentation and later during the disease course with its prevalence increasing at each relapse. Although therapeutic interventions have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.